Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2501307 | 0.85 | CHRNB2 (0.42) | OPRK1DRD2DRD3DRD4ESR1 | |
| SCHEMBL6583849 | 0.77 | CHRNB2 (0.34) | CA1CA2 | |
| SCHEMBL3028639 | 0.77 | TRPM5 (0.41) | — | |
| SCHEMBL7540183 | 0.77 | OPRM1 (0.38) | OPRM1ACHE | |
| SCHEMBL10292643 | 0.76 | FYN (0.40) | DRD2DRD3DRD4MAOA | |
| Hydrochloric Acid SCHEMBL3020631 | 0.76 | CHRNB2 (0.33) | — | |
| SCHEMBL3161060 | 0.73 | OPRM1 (0.44) | OPRK1OPRM1OPRD1DRD2DRD3 | |
| SCHEMBL7439467 | 0.73 | OPRM1 (0.44) | OPRK1OPRM1OPRD1DRD2DRD3 | |
| SCHEMBL1722308 | 0.71 | GRIN2D (0.41) | — | |
| SCHEMBL7273323 | 0.71 | DRD2 (0.46) | OPRK1DRD2DRD3DRD4ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1146041-B1 | Derivatives of heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane and their use as inhibitors of the recapture of serotonine and of noradrenaline | SERVIER LAB (FR) | 2003-11-12 | — | — | EP | disclosed |
| US-6420413-B2 | 1-(6-((DIMETHYLAMINO)METHYL)-1-METHYL-2,3,5,6-TETRAHYDRO-1H -CYCLOBUTA(F) INDOL-6-YL)CYCLOHEXANOL, FOR EXAMPLE; TREATING PSYCHOLOGICAL DISORDERS SUCH AS DEPRESSION, PANIC ATTACKS, PHOBIAS, DRUG ABUSE, AS WELL AS OBESITY AND BULEMIA | LES LABORATORIES SERVIER (FR) | 2002-07-16 | — | — | US | disclosed |
| EP-0940386-B1 | Benzocyclobutan compounds, their process for preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-05-22 | — | — | EP | disclosed |
| EP-1038873-B1 | Benzo(3,4)cyclobuta(1,2-c)pyrrole derivatives as inhibitors of serotonine reuptake | SERVIER LAB (FR) | 2002-05-02 | — | — | EP | disclosed |
| US-20020019380-A1 | Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds | LES LABORATOIRES SERVIER (FR) | 2002-02-14 | — | — | US | disclosed |
| EP-1146041-A1 | Derivatives of heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane and their use as inhibitors of the recapture of serotonine and of noradrenaline | ADIR ET COMPAGNIE (FR) | 2001-10-17 | — | — | EP | disclosed |
| US-6153640-A | FOR TREATING DEPRESSION, PANIC ATTACKS, OBSESSIVE-COMPULSIVE DISORDERS, PHOBIAS, IMPULSIVE DISORDERS, DRUG ABUSE OR ANXIETY | ADIR ET COMPAGNIE (FR) | 2000-11-28 | — | — | US | disclosed |
| EP-1038873-A2 | Benzo(3,4)cyclobuta(1,2-c)pyrrole derivatives as inhibitors of serotonine reuptake | ADIR ET COMPAGNIE (FR) | 2000-09-27 | — | — | EP | disclosed |
| US-6107345-A | ANTIDEPRESSANT; PSYCHOLOGICAL DISORDERS | ADIR ET COMPAGNIE (FR) | 2000-08-22 | — | — | US | disclosed |
| EP-0940386-A1 | Benzocyclobutan compounds, their process for preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1999-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019380-A1 | Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds | HSD3B2, HSD3B1, NR1H3 | OPRK1 329/4885OPRM1 128/4885OPRD1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.